We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EOM613

News List

EOM Pharmaceuticals, Inc. and Immunocellular Therapeutics, Ltd. Announce Entry into and Close of Definitive Merger Agreement AmericanPharmaceuticalReview
December 06, 2021
EOM Pharmaceuticals, Inc., a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd. announced that the companies have entered into and closed on a merger agreement pursuant to which the shareholders of EOM are now...
EOM Pharmaceuticals Announces First Patients Dosed In R1: RESCUE Phase 1/2a Open-label Trial Evaluating EOM613 In Hospitalized COVID-19 Patients With Severe Symptoms In Brazil prnewswire
August 25, 2021
EOM announced the first patients have been dosed in R1: RESCUE, a proof-of-concept Phase 1/2a open-label multicenter clinical study in Brazil to evaluate safety, tolerability, and preliminary efficacy of EOM613 in hospitalized COVID-19 infected patients